PFS after ibrutinib discontinuation. All patients on the IR arm of E1912 trial who started IR treatment (patients who did not start IR were excluded). Patients who started alternative therapy censored at the time of starting alternative therapy. (A) PFS after ibrutinib discontinuation. (B) PFS after ibrutinib discontinuation by IGHV status. (C) PFS after ibrutinib discontinuation by Döhner classification. (D) PFS after ibrutinib discontinuation by duration of ibrutinib treatment before discontinuation.